106 related articles for article (PubMed ID: 7546811)
1. [Treatment of complicated Parkinson disease with a solution of levodopa-carbidopa and ascorbic acid].
Linazasoro G; Gorospe A
Neurologia; 1995; 10(6):220-3. PubMed ID: 7546811
[TBL] [Abstract][Full Text] [Related]
2. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
3. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
4. [Clinical experience in switching patients from standard levodopa to a controlled-release levodopa].
Leiva Santana C; Galvañ Berenguer B; Gómez García J; Cabello López J
Neurologia; 1996 Jan; 11(1):1-9. PubMed ID: 8714169
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
6. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
7. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
Shoulson I
Adv Neurol; 1983; 37():259-66. PubMed ID: 6134445
[No Abstract] [Full Text] [Related]
8. [A year of treatment with carbidopa and levodopa in Parkinsonian patients].
Martínez-Lage JM; Marti-Massó JF; Delgado G; Carreray N; Del Amo F
Rev Clin Esp; 1974 Sep; 134(6):535-42. PubMed ID: 4450036
[No Abstract] [Full Text] [Related]
9. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
Klivényi P; Vécsei L
Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
11. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
Nutt JG; Woodward WR; Anderson JL
Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
[TBL] [Abstract][Full Text] [Related]
12. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
[No Abstract] [Full Text] [Related]
13. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
[TBL] [Abstract][Full Text] [Related]
14. Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
Yang HJ; Ehm G; Kim YE; Yun JY; Lee WW; Kim A; Kim HJ; Jeon B
J Neurol Sci; 2017 Jun; 377():6-11. PubMed ID: 28477709
[TBL] [Abstract][Full Text] [Related]
15. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
16. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.
Eggert K; Schrader C; Hahn M; Stamelou M; Rüssmann A; Dengler R; Oertel W; Odin P
Clin Neuropharmacol; 2008; 31(3):151-66. PubMed ID: 18520982
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.
Blindauer K; Shoulson I; Oakes D; Kieburtz K; Schwid S; Fahn S; Stern M; Goetz C; Nutt J; Goren S; Sayag N; Scolnik M; Levy R; Eyal E; Salzman P; Pagano M;
Arch Neurol; 2006 Feb; 63(2):210-6. PubMed ID: 16476809
[TBL] [Abstract][Full Text] [Related]
18. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
20. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
